Navigation Links
Angiotech Pharmaceuticals announces the commercial launch of the Option(TM) Inferior Vena Cava Filter in the United States
Date:8/20/2009

r materially from our actual results. These operating risks include: our ability to attract and retain qualified personnel; our ability to successfully complete pre-clinical and clinical development of our products; changes in our business strategy or development plans; our failure to obtain patent protection for discoveries; loss of patent protection resulting from third-party challenges to our patents; commercialization limitations imposed by patents owned or controlled by third parties; our ability to obtain rights to technology from licensors; liability for patent claims and other claims asserted against us; our ability to obtain and enforce timely patent and other intellectual property protection for our technology and products; the ability to enter into, and to maintain, corporate alliances relating to the development and commercialization of our technology and products; market acceptance of our technology and products; our ability to successfully manufacture, market and sell our products; the availability of capital to finance our activities; our ability to restructure and to service our debt obligations; and any other factors referenced in our other filings with the applicable Canadian securities regulatory authorities or the Securities and Exchange Commission ("SEC"). For a more thorough discussion of the risks associated with our business, see the "Risk Factors" section in our annual report for the year ended December 31, 2008 filed with the SEC on Form 10-K, and our quarterly report for the three months ended June 30, 2009 filed with the SEC on Form 10-Q.

Given these uncertainties, assumptions and risk factors, investors are cautioned not to place undue reliance on such forward-looking statements. Except as required by law, we disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained in this press release to reflect future results, events or development
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Angiotech receives approval for Quill(TM) SRS PDO, MONODERM(TM), Polypropylene and Nylon product lines for sale in Brazil
2. Angiotechs Licensee, Cook Medical, Announces CE Mark Approval and European Launch of the Zilver(R) PTX(R) Stent
3. Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009
4. Angiotech Pharmaceuticals announces launch of Quill SRS product codes for laparoscopic gynecology procedures
5. Angiotech Pharmaceuticals, Inc. announces filing of shelf-registration statement
6. Angiotech Pharmaceuticals announces FDA approval of TAXUS(R) Liberte(R) Long Stent
7. Angiotech Pharmaceuticals, Inc. announces conference call and webcast
8. Angiotech Pharmaceuticals announces FDA 510(k) clearance of the Option(TM) Inferior Vena Cava Filter
9. Angiotech Enters License, Distribution and Supply Agreements for Fibrin and Thrombin Technologies with Haemacure Corporation
10. Angiotech Pharmaceuticals announces FDA approval of next-generation TAXUS(R) Liberte(R) Atom(TM) Stent system
11. Angiotechs corporate partner, Boston Scientific, announces launch of third-generation TAXUS(R) Element(TM) Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... 20, 2014 Convey Computer , ... team from Iowa State University won first place in ... a Convey HC-2ex, the team’s solution achieved the highest ... than the second place finisher. , Experts from all ... the month long challenge, using a variety of design ...
(Date:10/20/2014)... PureTech , a science and ... problems, announced today the closing of a $55 ... Invesco Perpetual, a $120 Billion group of funds. ... existing pipeline forward and to advance new healthcare ... creativity to really go for the big ideas ...
(Date:10/19/2014)... 2014 OCTOBER 20-22, 2014: ... ABIM will take place at the ... ABIM 2014 is now available at ... companies and organizations from all over the ... on the latest products and developments on ...
(Date:10/19/2014)... 2014 The report "Chocolate, Cocoa Beans, ... Prices, Geography Trend and Forecast (2011 - 2016)," ... geography and studies the major market drivers, restraints, and ... and Asia. , The global chocolate market is expected ... in 2016 at an estimated CAGR of 2.7% from ...
Breaking Biology Technology:Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 2Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 3Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 4
... , SPRINGFIELD, Ill., July 23 St. ... Midwest to acquire a dual console da Vinci surgical robot, and one ... , , , , ... gives surgeons an enhanced three-dimensional view of the operative field and greater ...
... SHANGHAI, July 22 /PRNewswire-Asia/ -- Since the ... ago for Sundia MediTech Company and,2 other CRO companies in ... CRO shipments has been shortened from 3 days to 1,day ... Sundia. , In light of the ...
... , , , ... today announced a relationship with Saigene Biotech, Inc. for the introduction ... technology in ASEAN nations, China, and Bangladesh. Global One, a ... Asian nations, specializes in helping emerging products and technologies find their ...
Cached Biology Technology:St. John's Hospital Acquires Latest Technology in Robotic-Assisted Surgery 2Sundia Shortens CRO Shipment Delivery Time with Express Customs Clearance in Shanghai 2Global One Consulting Announces Exclusive Contract to Expand Saigene Biotech, Inc. Sales in Emerging Markets 2Global One Consulting Announces Exclusive Contract to Expand Saigene Biotech, Inc. Sales in Emerging Markets 3
(Date:10/15/2014)... ability to assess the pandemic risk from strains of ... must not allow ourselves to become complacent that the ... consortium of scientists. , Influenza pandemics arise when a ... to develop widespread immunity – spreads in the human ... past 100 years, the worst of which – the ...
(Date:10/15/2014)... in female mice to an enzyme activated by the ... resistant to respiratory infections than males. Now, an international ... bacterial pneumonia in female mice is linked to the ... that this enzyme is ultimately activated by the release ... lead by Professor Lester Kobzik at the Harvard University ...
(Date:10/14/2014)... thieves, prostate cancer tumors scavenge and hoard copper that ... avarice may be a fatal weakness. , Researchers ... prostate cancer cells by delivering a trove of copper ... cells brimming with the mineral, leaving non-cancer cells healthy. ... commercially available for other uses, could soon be tested ...
Breaking Biology News(10 mins):Scientists 'must not become complacent' when assessing pandemic threat from flu viruses 2Prostate cancer's penchant for copper may be a fatal flaw 2
... In a study to be published online this week in ... researchers report the discovery of a novel hepatitis C-like virus ... gives scientists new insights into how hepatitis C in humans ... a model system to study how it causes disease. ...
... Drug Administration requires every drug they certify to be ... current gold standard for this is the limulus amoebocyte ... horseshoe crabs, which strangely enough is blue, to test ... caused by bacterial infections. But researchers at the ...
... popular conception that behaviours such as repetitive hand-washing, characteristic ... to disturbing obsessive fears. The study, conducted ... University of Amsterdam, found that in the case of ... precursors to the disorder, and that obsessions may simply ...
Cached Biology News:Discovery of canine hepatitis C virus opens up new doors for research on deadly human pathogen 2Discovery of canine hepatitis C virus opens up new doors for research on deadly human pathogen 3Replacing the blue bloods 2New research provides insight into how OCD develops 2
... Reverse Transcriptase (M-MLV RT) is an RNA-dependent DNA ... with long messenger RNA templates (>5kb). The enzyme ... M-MLV and consists of a single subunit with ... activity of M-MLV RT is weaker than the ...
... Useful for the determination of digitonin and digoxin. ... EDTA Na 4 and 0.06% NaCl Preparation ... al., Biochem. Biophys. Res. Commun., 19, 755 ... mole of inorganic phosphorus from ATP per min ...
kismet (dK-20)...
... Thermo Hybaid's unique Electro-4 design allows ... the Electro-4 it is possible to run ... tank, by stacking up to four,horizontal gels. ... adjustable according to the number of gels ...
Biology Products: